Wide Ranks

ELTX

Elicio Therapeutics, Inc.

5.05

Top Statistics
Market Cap 54 M Forward PE -1.68 Revenue Growth 0.00 %
Current Ratio 0.88 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.50 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 3 M Total Cash Per Share 0.3180 Total Debt 6 M
Total Debt To Equity Current Ratio 0.88 Book Value Per Share 1.18
All Measures
Short Ratio 249.00 % Message Board Id finmb_214936128 Shares Short Prior Month 39357
Return On Equity -3.53 City Boston Uuid f5a7063e-a200-3645-afdf-a5955dd38a4c
Previous Close 4.88 First Trade Date Epoch Utc 1 B Book Value 1.18
Total Debt 6 M Volume 12389 Price To Book 4.27
Last Split Date 1 B Fifty Two Week Low 2.96 Total Cash Per Share 0.3180
Shares Short Previous Month Date 1 B Target Median Price 9.50 Audit Risk 10
Max Age 86400 Recommendation Mean 2.00 Sand P52 Week Change 0.3133
Target Mean Price 9.50 Net Income To Common -38665000 Short Percent Of Float 0.0049
Implied Shares Outstanding 10 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 34880 Average Volume10days 34880 Total Cash 3 M
Next Fiscal Year End 1 B Held Percent Insiders 0.2608 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 4.88 Target Low Price 9.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 4.86 Open 5.00 Free Cashflow -22082000
State MA Dividend Yield 0.00 % Return On Assets -0.9680
Time Zone Short Name EST Board Risk 6 Trailing Eps -3.44
Day Low 4.95 Address1 451 D Street Shares Outstanding 10 M
Compensation Risk 8 Price Hint 2 Target High Price 10.00
Website https://elicio.com 52 Week Change -0.1789 Average Volume 19509
Forward Eps -2.57 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 46.30 % Last Split Factor 1:10 Regular Market Day High 5.11
Is_sp_500 False Profit Margins 0.00 % Fifty Two Week High 11.45
Day High 5.11 Shares Short 42962 Regular Market Open 5.00
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0040 Operating Cashflow -36130000 Currency USD
Time Zone Full Name America/New_York Market Cap 54 M Is_nasdaq_100 False
Zip 02210 Quote Type EQUITY Industry Biotechnology
Long Name Elicio Therapeutics, Inc. Overall Risk 8 Regular Market Day Low 4.95
Held Percent Institutions 0.0582 Current Price 5.05 Address2 5th Floor Suite 501
Enterprise To Ebitda -1.50 Financial Currency USD Current Ratio 0.88
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country United States
Float Shares 8 M Two Hundred Day Average 5.89 Governance Epoch Date 1 B
Enterprise Value 61 M Forward PE -1.68 Regular Market Volume 12389
Ebitda -40998000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer.

Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations.

The company is headquartered in Boston, Massachusetts.